In a press release, Inovio said its vaccine led to “immunological response rates” in 34 of 36 patients in the trial, but did not disclose how many patients produced antibodies that neutralize the coronavirus — data key to determining whether the vaccine could protect against infection.
Inovio’s vaccine works by injecting synthetic DNA that codes for protective antibodies
Altimmune:
No comments:
Post a Comment